Cover Image
市場調查報告書

適用於癌症管理的液體活檢技術革新

Innovations in Liquid Biopsy Techniques for Cancer Management

出版商 Frost & Sullivan 商品編碼 553373
出版日期 內容資訊 英文 66 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
適用於癌症管理的液體活檢技術革新 Innovations in Liquid Biopsy Techniques for Cancer Management
出版日期: 2017年08月01日 內容資訊: 英文 66 Pages
簡介

本報告針對使腫瘤分析、治療監測及精準腫瘤應用療法成為可能的低侵入性暨非侵入性的活體組織切片平台,關注循環腫瘤DNA (ctDNA) 、循環腫瘤細胞 (CTC)與細胞外囊泡 (EV) ,進行了綜合分析,並提供了技術、臨床、專利與應用趨勢的評價。

第1章 執行摘要

第2章 技術快照概述

  • 主要液體活檢 (LB) 標記概述
  • 構成循環腫瘤DNA (ctDNA) 、循環腫瘤細胞 (CTC) 及細胞外囊泡 (EV) 的主要液體活檢標記

第3章 ctDNA的技術分析

  • 預期可促進ctDNA分析的新一代測序平台
  • 適於分析ctDNA的PCR型技術概述
  • 適於評價ctDNA的新一代測序工具
  • 可進行綜合基因組分析的新興ctDNA技術
  • ctDNA領導了臨床實驗研究中的分析、治療監測應用
  • 中國的ctDNA型技術專利情況領先全球
  • 美國投入ctDNA型專案的研究資金在2015-2016年超過了5億美元
  • ctDNA生物標記研究預期會加速疾病、治療分析應用發展
  • 運用於整體癌症診斷的表觀遺傳學工具
  • 實現對癌症的個別管理

第4章 可檢測出CTC的技術

  • 循環腫瘤細胞使癌症綜合分析成為可能
  • 適用於CTC的細胞分析可以考查出癌症前兆
  • 促進CTC分子分析的技術預期將轉換成癌症管理
  • 強化CTC分析的微流控及成像技術的新應用
  • 中國的CTC專利情況領先全球
  • CTC型專案的NIH資金在2015-2016年已超過1億5000萬美元
  • CTC預期可橫跨數種癌症,在疾病分析、治療分析及預後應用上取得領先
  • 適於液體細胞生物檢定法的ctDNA與CTC分析的結合
  • 經美國FDA認可的CTC生物檢定法

第5章:細胞外囊泡 (EV) 的評價技術

  • 外吐小體預期在癌症液體活檢的用途中會受到高度矚目
  • Affinity Capture及微流控技術預期在不久的將來會強化外吐小體的單離及檢出
  • 蛋白質組與核酸檢定法技術的進步,預期可強化外吐小體標記的檢出
  • 美國的EV型技術資金在2015-2016年超過了2億5000萬美元
  • 外吐小體標記預期將在疾病分析、治療監測應用上取得領先
  • 外吐小體型液體細胞生物檢定法
  • 適用於精準腫瘤治療的外吐小體型液體細胞生物檢定法
  • 為了強化EV單離而生的平台

第6章 影響分析、未來展望

  • 主要技術促進因子的總結
  • 技術進步、偏好低侵入性方法的增加,預期將推進液體活檢平台的發展
  • 主要技術課題總結
  • 提高檢定法精確度及生物標記的臨床有用性,是液體活檢的主要課題
  • 液體活檢平台預期將轉換成疾病分析及精準醫療應用

第7章 成長機會、企業活動

  • 成長機會1:ctDNA
  • 成長機會2:CTC
  • 成長機會3:EV
  • 達到成功、成長的策略必須條件

第8章 附錄

第9章 關於FROST AND SULLIVAN

目錄
Product Code: D7CC

Liquid Biopsy Technologies Likely to Lead the Transformation of Cancer Profiling and Personalized Treatment Strategies

This research service encompasses a comprehensive analysis of minimally-invasive and non-invasive biopsy platforms that enable enhanced tumor profiling, treatment monitoring and precision oncology applications. This service primarily focuses on the use of circulating tumor DNA (ctDNA) circulating tumor cells (CTCs) and extracellular vesicles (EVs), derived from bio-fluids such as blood and urine, for molecular analysis across research and healthcare settings. This study also evaluates the technology, clinical, patent, and application landscapes prevalent across liquid biopsy settings, while providing valuable insights across its global technological impact and future perspectives.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Research Scope
  • 1.2. Research Methodology
  • 1.2. Research Methodology (Continued)
  • 1.3. Key Findings

2.0. TECHNOLOGY SNAPSHOT AND OVERVIEW

  • 2.1. Overview of Key Liquid Biopsy (LB) Markers
  • 2.2. Key Liquid Biopsy Markers Comprise Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and Extracellular Vesicles (Evs)

3.0. TECHNOLOGIES ANALYZING CTDNA

  • 3.1. Next-Generation Sequencing Platforms Likely to Fuel ctDNA Analysis
  • 3.2. Overview of PCR-Based Technologies for ctDNA Analysis
  • 3.3. Next-Generation Sequencing Tools for ctDNA Assessment
  • 3.4. Emerging ctDNA Technologies Likely to Enable Comprehensive genome Profiling
  • 3.5. ctDNA Leads Profiling and Therapy Monitoring Applications in Clinical Trial Studies
  • 3.6. China Leads the Global Patent Landscape for ctDNA-based Technologies
  • 3.7. Research Funding in US for ctDNA-based Projects Exceed $50M in 2015-2016 Period
  • 3.8. ctDNA Biomarkers Studies Likely to Accelerate Disease and Treatment Profiling Applications
  • 3.9. Leveraging Epigenetic Tools across Cancer Diagnostics
  • 3.10. Enabling Personalized Management of Cancer

4.0. TECHNOLOGIES ENABLING CTC DETECTION

  • 4.1. Circulating Tumor Cells Enable Comprehensive Analysis of Cancer
  • 4.2. Cellular Analytics for CTCs Enable Prognostic Insights for Cancer
  • 4.3. Technologies Facilitating Molecular Analysis of CTCs Likely to Transform Cancer Management
  • 4.4. Emerging Use of Microfluidic and Imaging Technologies Enhance CTC Analysis
  • 4.5. China Leads the Global Patent Landscape for CTCs
  • 4.6. NIH funding for CTC-based Projects Exceeded $150 million during 2015-2016
  • 4.7. CTCs Likely to Lead Disease Profiling, Treatment Profiling and Prognostic Applications across Several Cancers
  • 4.8. Combining ctDNA and CTC Analyses for Liquid Biopsy Assays
  • 4.9. US FDA Approved CTC Assay

5.0. TECHNOLOGIES FOR ASSESSMENT OF EXTRACELLULAR VESICLES

  • 5.1. Exosomes Likely to Garner Growing Attention across Cancer Liquid Biopsy Applications
  • 5.2. Affinity Capture and Microfluidics techniques Likely to Enhance Exosome Isolation and Detection in the Near Future
  • 5.3. Advances across Proteomic and Nucleic Acid Assay Techniques Likely to Enhance Exosome Markers Detection
  • 5.4. North America Leads the Global Patent Landscape for Extracellular Vesicle-based Technologies
  • 5.5. US Research Funding for EV-based Technologies Exceeds $250 Million during 2015-2016
  • 5.6. Exosomal Markers Likely to Lead Disease Profiling and Treatment Monitoring Applications
  • 5.7. Exosome-based Liquid Biopsy Assays for Precision Oncology
  • 5.8. Novel Platforms for Enhanced Isolation of Evs

6.0. IMPACT ANALYSIS AND FUTURE PERSPECTIVES

  • 6.1. Summary of Key Technology Drivers
  • 6.2. Technology Advancements and Rising Preference for Minimally Invasive Methods Likely to Fuel Liquid Biopsy Platforms
  • 6.3. Summary of Key Technology Challenges
  • 6.4. Enhancing Assay Accuracy and Clinical Utility of Biomarkers Constitute Key Challenges across Liquid Biopsy Tests
  • 6.5. Liquid Biopsy Platforms Likely to Transform Disease Profiling and Precision Medicine Applications

7.0. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • 7.1. Growth Opportunity 1: ctDNA
  • 7.2. Growth Opportunity 2: CTCs
  • 7.3. Growth Opportunity 3: Evs
  • 7.4. Strategic Imperatives for Success and Growth

8.0. APPENDIX

  • 8.1. Key Contacts
  • 8.1. Key Contacts (continued)
  • Legal Disclaimer

9.0. THE FROST & SULLIVAN STORY

  • 9.1. The Frost & Sullivan Story
  • 9.2. Value Proposition: Future of Your Company & Career
  • 9.3. Global Perspective
  • 9.4. Industry Convergence
  • 9.5. 360° Research Perspective
  • 9.6. Implementation Excellence
  • 9.7. Our Blue Ocean Strategy
Back to Top